- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02343146
Healthy Eating, Physical Activity, and Glycemic Control in Young Children With T1D
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Young children (<5 years) comprise a growing number of persons diagnosed with type 1 diabetes (T1D)--a costly, chronic illness [1, 2]. Early age at diagnosis and poor glycemic control during these early years increases risk for development of serious diabetes-related complications (ref). Thus, these years represent a critical period for establishing proper patterns of T1D management and glycemic control in young children [7]. In addition to young children's daily reliance on parents for T1D care, such as blood glucose (BG) monitoring and insulin administration, careful attention must be paid to diet and physical activity regulation. Behavioral interventions supporting and enhancing T1D management among parents of these young children have the potential for significant impact on children's glycemic control as well as developmentally important outcomes, and may reduce both immediate and long-term clinical and public health burdens of T1D complications.
Although multicomponent behavioral interventions for parents of young children with T1D demonstrate potentially promising psychosocial outcomes [8-10], concomitant improvements in children's glycemic control from these interventions remain elusive. Two critical areas not yet addressed directly in interventions is the promotion of healthy eating and engagement in consistent physical activity in young children, nor the behavioral strategies to support parents in these challenges that occur multiple times daily (e.g., each meal/snack, each physical activity experience). The current proposal utilizes the extensive expertise of our multidisciplinary team to refine and pilot an innovative and translatable intervention targeting eating and physical activity behaviors directly associated with glycemic control in young children that can ultimately be adopted outside of research settings. The investigators' prior successful clinical research efforts engaging parents of young children with T1D in behavioral interventions (R01 DK080102) places them in a unique position to further design and pilot this intervention and ultimately be well poised to run a future full-scale efficacy trial.
The current proposal shifts the investigators' prior interventions' focus away from parental stress and instead highlights behavioral strategies promoting healthy eating and engagement in consistent physical activity, as well as nutrition and physical activity links to glycemic control. Based upon positive preliminary data the investigators will utilize novel assessment (accelerometry, personal activity monitors (PAM), and continuous glucose monitors (CGM)) and intervention components (parent consultants and trained intervention telephone counselors), with the intervention being delivered via telephone and in-person. The investigators will follow an iterative mixed methods approach to refine the intervention from Phase 1 to Phase 2. During phase 1 the investigators will pre-pilot the intervention by examining feasibility and acceptability in 10 parents (of children ages 1-5 yrs with a minimum of 1 yr duration of diabetes). The investigators will use qualitative interviews, questionnaire, and objective (CGM, accelerometry) data to help refine key intervention components and discern best areas for intervention target (i.e., low glycemic breakfast or different meal; planned physical activity or increasing steps through daily living; PAM or accelerometry). This phase will include soliciting feedback from the advisory board leading to further refinement of the intervention and manual of procedures. During phase 2 the investigators will execute a pilot randomized trial evaluating whether glycemic control and developmentally-important outcomes (child feeding and physical activity) in young children with T1D can be favorably impacted. Phase 2 will include 60 parents (of children ages 1-5 yrs) randomly allocated to either the intervention (n=30) or standard care (n=30). Assessments will be completed 3 times (T1, T2-immediately post intervention, and T3-6 months post-intervention). Clinical, biological, and behavioral diabetes outcomes will be measured. Specific Aims for this trial are:
Aim 1. Pilot test and refine innovative and feasible assessment and intervention components for T1D control in young children, and examine acceptability and impact in parents of young children. At the conclusion of Phase 1, this Aim results in an innovative intervention program, supported by state of the art assessment tools and preliminary data. The investigators hypothesize that the intervention will be associated with high feasibility and acceptability, improved T1D management, and reduction of behavioral challenges related to eating and physical activity.
Aim 2. Determine the intervention's efficacy for improving young children's glycemic control and parent's management of eating and physical activity behaviors. The investigators hypothesize that the Phase 2 pilot will demonstrate that relative to usual care, the intervention will evidence 1) Significantly better glycemic control (i.e., HbA1c <8.5% and higher percentage of BG levels in the 100-200 mg/dl range, per ADA recommendations) and 2) Significantly fewer child feeding and activity behavior problems (e.g., food refusal, dawdling at mealtimes, physical inactivity). 3. Mediating effects of eating and physical activity on glycemic control will also be explored.
Aim 3. Explore the feasibility of program implementation in a larger scale efficacy trial, and in clinical T1D management. Using a purposeful sample subset of parents in the intervention condition, the investigators will use qualitative interviews to further examine the impact of the intervention, and assist in further refinement prior to a larger scale trial. The investigators will also interview advisory board members including members of the health care team to gather system- and provider-level data about key capacities to inform the integration of our intervention into patient/work flow in anticipation of a larger efficacy trial.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
District of Columbia
-
Washington, District of Columbia, États-Unis, 20010
- Children's Research Institute
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- parent of a child age 1-5 and their target child (children are considered secondary participants)
- child with a minimum of 1 year duration of T1D
- parents must have ready and consistent access to a mobile telephone with text messaging capability
Exclusion Criteria:
- Parent participants cannot have serious mental illness or developmental disability that would limit participation
- Child participants cannot have other life-threatening disease (e.g., cancer, cystic fibrosis) or developmental disability (e.g., autism, mental retardation)
- Parent participants must be able to adequately understand, speak, and read English
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Type One Training (TOT)
The intervention group will receive the proposed intervention composed of peer parent consultants, telephone and in-person sessions with a trained interventionist, and SMS text messaging aimed at improving child glycemic control through improved nutrition and physical activity.
|
The intervention is comprised of a number of modes of delivery including in person, use of parent peer consultant, telephone intervention, and text messaging.
The intervention is based on Social Cognitive Theory and previous work of the investigators.The focus of the intervention is on working with parents to improve child eating and physical activity behaviors as a means of improving glycemic control in very young children with type 1 diabetes.
|
Aucune intervention: Comparison
The comparison group will receive usual care with the diabetes team.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Glycemic Control/HbA1c
Délai: 6 months post intervention
|
Change in glycemic control from baseline to 6 months post intervention
|
6 months post intervention
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Child eating as measured by Remote Food Photography by the parent
Délai: 6 months post intervention
|
Change in child eating behaviors from baseline to 6 months post intervention
|
6 months post intervention
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Randi Stresiand, PhD, Children's National Research Institute
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 5649
- DP3DK103998 (Subvention/contrat des NIH des États-Unis)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Diabète sucré, type 1
-
Eledon PharmaceuticalsRetiréDiabète sucré de type 1 fragileÉtats-Unis
-
Ain Shams UniversityInconnueDiabète sucré de type 1 avec hypoglycémie | diabète de type 1Egypte
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)ComplétéDiabète sucré de type 1 | DT1 | DT1 | Diabète sucré de type 1 d'apparition récenteÉtats-Unis, Australie
-
Medical College of WisconsinRecrutementDiabète de type 1 | Diabète sucré de type 1 | diabète de type 1États-Unis
-
Spiden AGDCB Research AGRecrutementDiabète sucré de type 1 | Diabète sucré de type 1 avec hypoglycémie | Diabète sucré de type 1 avec hyperglycémieSuisse
-
Shanghai Changzheng HospitalRecrutementDiabète sucré de type 1 fragileChine
-
Instytut Diabetologii Sp. z o.o.National Center for Research and Development, Poland; Nalecz Institute of...InconnueDiabète sucré de type 1 avec hyperglycémie | Diabète sucré de type 1 avec hypoglycémiePologne
-
Capillary Biomedical, Inc.ComplétéDiabète sucré, type 1 | Diabète de type 1 | Diabète sucré de type 1 | Diabète sucré, dépendant de l'insuline, 1Australie
-
Poznan University of Medical SciencesInconnueDiabète sucré de type 1 | Rémission du diabète de type 1 | Complications chroniques du diabètePologne
-
Capillary Biomedical, Inc.RésiliéDiabète de type 1 | Diabète sucré de type 1 | Diabète sucré, type I | Diabète sucré, dépendant de l'insuline, 1 | IDDML'Autriche
Essais cliniques sur Type One Training (TOT)
-
Northwestern UniversityNational Cancer Institute (NCI)RetiréCarcinome du sein | Tumeur maligne métastatique dans le cerveau | Tumeur maligne métastatique chez les leptoméningesÉtats-Unis
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityRésiliéMyélofibrose primaire | Anémie | Lymphome hodgkinien récurrent | Lymphome hodgkinien réfractaire | Cancer du sein anatomique de stade IV AJCC v8 | Leucémie myéloïde aiguë récurrente | Syndrome myélodysplasique récurrent | Leucémie myéloïde aiguë réfractaire | Leucémie myélomonocytaire chronique réfractaire et d'autres conditionsÉtats-Unis